137 related articles for article (PubMed ID: 3361537)
21. Juvenile systemic sclerosis: report of three cases and review of Japanese published work.
Aoyama K; Nagai Y; Endo Y; Ishikawa O
J Dermatol; 2007 Sep; 34(9):658-61. PubMed ID: 17727371
[TBL] [Abstract][Full Text] [Related]
22. [Anticentromere antibodies and lung disease without skin involvement].
Fernández-Fernández FJ; Sesma P; Facio A; Guerra JL; González-Moraleja J
An Med Interna; 1997 Apr; 14(4):196-8. PubMed ID: 9181818
[TBL] [Abstract][Full Text] [Related]
23. Autoantibodies in systemic sclerosis.
Steen VD
Semin Arthritis Rheum; 2005 Aug; 35(1):35-42. PubMed ID: 16084222
[TBL] [Abstract][Full Text] [Related]
24. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
25. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients.
Poormoghim H; Lucas M; Fertig N; Medsger TA
Arthritis Rheum; 2000 Feb; 43(2):444-51. PubMed ID: 10693887
[TBL] [Abstract][Full Text] [Related]
26. Studies of scleroderma at the Alfred Hospital, Melbourne.
Barnett AJ
Intern Med J; 2006 Aug; 36(8):513-8. PubMed ID: 16866656
[TBL] [Abstract][Full Text] [Related]
27. Anticentromere antibody and immunoglobulin allotypes in scleroderma.
Chen ZY; Fedrick JA; Pandey JP; Silver R; Maricq HR; Fudenberg HH; Dobson RL; Ainsworth SK
Arch Dermatol; 1985 Mar; 121(3):339-44. PubMed ID: 3883903
[TBL] [Abstract][Full Text] [Related]
28. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features.
Volpe A; Biasi D; Caramaschi P; Mantovani W; Bambara LM; Canestrini S; Ferrari M; Poli G; Degan M; Carletto A; Pieropan S; Minuz P
Rheumatology (Oxford); 2006 Mar; 45(3):314-20. PubMed ID: 16219641
[TBL] [Abstract][Full Text] [Related]
29. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
30. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Steen V; Medsger TA
Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
[TBL] [Abstract][Full Text] [Related]
31. [Study of the capillary microscopy changes in scleroderma and their association with organ disease, clinical manifestations and disease progression].
Simeón CP; Fonollosa V; Vilardell M; Armadans L; Lima J; Cuenca R; Solans R; Espinach J
Med Clin (Barc); 1991 Nov; 97(15):561-4. PubMed ID: 1805078
[TBL] [Abstract][Full Text] [Related]
32. Relationship between nailfold capillary microscopy and salivary capillary basement membrane width in Raynaud's disease and progressive systemic sclerosis.
DeBure C; Fiessinger JN; Priollet P; Camilleri JP; Vayssairat M; Kazandjian S; Housset E
J Rheumatol; 1985 Apr; 12(2):279-82. PubMed ID: 4032402
[TBL] [Abstract][Full Text] [Related]
33. Microvascular involvement in systemic sclerosis: capillaroscopic findings.
Grassi W; Medico PD; Izzo F; Cervini C
Semin Arthritis Rheum; 2001 Jun; 30(6):397-402. PubMed ID: 11404822
[TBL] [Abstract][Full Text] [Related]
34. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
[TBL] [Abstract][Full Text] [Related]
35. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients.
Sulli A; Secchi ME; Pizzorni C; Cutolo M
Ann Rheum Dis; 2008 Jun; 67(6):885-7. PubMed ID: 18037628
[TBL] [Abstract][Full Text] [Related]
36. Localized and systemic scleroderma.
Hawk A; English JC
Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
[TBL] [Abstract][Full Text] [Related]
37. Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon.
Anderson ME; Allen PD; Moore T; Hillier V; Taylor CJ; Herrick AL
J Rheumatol; 2005 May; 32(5):841-8. PubMed ID: 15868619
[TBL] [Abstract][Full Text] [Related]
38. Classification of systemic sclerosis. Visions and reality.
Wollheim FA
Rheumatology (Oxford); 2005 Oct; 44(10):1212-6. PubMed ID: 15870151
[TBL] [Abstract][Full Text] [Related]
39. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy.
Chandran G; Smith M; Ahern MJ; Roberts-Thomson PJ
Aust N Z J Med; 1995 Dec; 25(6):688-94. PubMed ID: 8770332
[TBL] [Abstract][Full Text] [Related]
40. [Clinical aspects of progressive systemic scleroderma (PSS). Multicenter studies of 194 patients].
Goerz G; Hammer G; Wirth G; Hornstein OP; Keller GJ; Altmeyer P; Holzmann H; Meigel W; Mensing H; Braun-Falco O
Hautarzt; 1986 Jun; 37(6):320-4. PubMed ID: 3522484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
